We are pleased to announce that the UltraGene Combo2Screen SARS-CoV-2 Assay has obtained Highly Satisfactory results (with a 100% accuracy for qualitative detection of all QCMD blinded samples, including with lowest viral load) in the context of the QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study. The QCMD is an independent International External Quality Assessment (EQA) / Proficiency Testing (PT) organisation, providing wide-ranging quality assessment services. This organisation primarily focuses on molecular infectious diseases.
Highly Satisfactory Accuracy for the UltraGene Combo2Screen SARS-CoV-2 Assay on the QCMD 2020 Coronavirus Outbreak Preparedness EQA Pilot Study
May 29, 2020